Authors:
Monali Tayade, Sampada Kulkarni
Download free PDF
Point of Care Ultrasound (POCUS) Market Size & Share 2026-2035
Report ID: GMI3325
|
Published Date: September 2026
|
Report Format: PDF/Excel/Dashboard/Platform
Download Free PDF
Explore Our Licensing Options:
Download Free PDF
Point of Care Ultrasound (POCUS) Market
Get a free sample of this report
What are you hoping to find?
Your PDF is on its way. Tell us little about your research goal, and we'll help you find the most relevant market insights.
Point of Care Ultrasound Market Size
The global point of care ultrasound market was valued at USD 4.2 billion in 2025, is estimated at USD 4.5 billion in 2026, and is projected to reach USD 9 billion by 2035, expanding at an 8% CAGR from 2026 to 2035.
Point of Care Ultrasound (POCUS) Market Key Takeaways
Market Leader: GE Healthcare led with over 22% market share in 2025.
Leading Players: Top 5 players in this market include Canon Medical Systems, Siemens Healthineers, Koninklijke Philips, Fujifilm, GE Healthcare, which collectively held a market share of 55% in 2025.
Demand is underpinned by the large clinical burden of chronic disease: noncommunicable diseases caused more than 43 million deaths in 2021, including over 19 million cardiovascular deaths. [1]World Health Organization, Noncommunicable diseases: mortality, updated 2021, who.int Population aging reinforces this demand because the global population aged 60 years and older is projected to rise from 1 billion in 2020 to 1.4 billion by 2030. [2]World Health Organization, Ageing and health fact sheet, 2024, who.int
Point-of-care ultrasound (POCUS) places image acquisition and clinical decision-making in the same encounter. Its scope spans portable console and trolley-based systems, as well as handheld probes connected to mobile devices, used across emergency, cardiac, obstetric, urologic, vascular, and musculoskeletal care. The commercial value of the category lies in replacing selected transfers to centralized imaging with immediate, focused assessment at the bedside, in procedure rooms, and in outpatient settings.
Hardware innovation is changing the procurement case. Semiconductor-based probes such as Butterfly's iQ3 consolidate broad imaging capability into a single handheld device, while AI-guided acquisition tools aim to reduce dependence on highly specialized sonography operators. GE HealthCare's Caption AI on the Vscan Air SL, for example, provides probe-positioning guidance and automated cardiac measurements, shifting part of the product differentiation from transducer specifications toward software-supported workflow.
North America represented approximately 42.45% of global revenue in 2025, or about USD 1.7 billion. Europe accounted for USD 1.1 billion, equivalent to approximately 25.95% of the market. Asia Pacific represented approximately 22.17% and is projected to expand at about 8.4% CAGR, ahead of the global rate. Latin America accounted for approximately 5.76% of 2025 revenue, while the Middle East & Africa represented approximately 3.6%.
GMI Analyst View
The market's 8% forecast growth does not depend solely on greater device penetration. Its durability rests on a change in how ultrasound is embedded in care delivery: portable imaging is increasingly purchased as an operating capability that combines hardware, image storage, quality review, training, and AI-enabled measurement. This shifts purchasing authority beyond radiology departments toward emergency, anesthesia, critical-care, and outpatient service lines that can connect faster diagnostic decisions to workflow and reimbursement outcomes.
The central tension is that broader access can expand unit volumes while weakening hardware pricing. Aging populations and chronic disease raise the number of encounters in which focused imaging can be useful, but handheld competition is making image quality less exclusive to premium systems. Suppliers with credible clinical software, regulatory clearance, and enterprise integration are therefore better positioned to protect recurring revenue than suppliers relying only on device sales.
Key Drivers
Chronic cardiovascular, respiratory, and metabolic conditions create recurring clinical situations in which focused bedside imaging can guide triage, volume assessment, vascular access, and monitoring. The demand effect is especially strong where centralized imaging capacity is constrained relative to patient volume. POCUS does not replace comprehensive imaging in every case, but it can reduce the number of encounters requiring transport, scheduling, and radiology-suite coordination.
Evidence from ward-emergency care illustrates the workflow benefit. In one controlled study, protocolized bedside POCUS increased adequate diagnostic rates from 80% to 94% and reduced median time to first treatment from 34 minutes to 15 minutes. [3]Laursen CB et al. Bedside POCUS during ward emergencies associated with improved diagnosis and outcome, 2021, pubmed.ncbi.nlm.nih.gov The implication for hospitals is not merely faster examination; it is a stronger economic case for systems that can archive images, document use, and support institutional quality assurance.
AI-assisted acquisition is widening the addressable user base. The Butterfly iQ3 received FDA clearance in January 2024 with features including automated B-line counting and bladder-volume calculation. Clarius reported 16 deployed AI technologies at year-end 2025, including six FDA-cleared models. These capabilities can reduce training friction for focused examinations, although clinical governance and competency requirements remain necessary.
Aging contributes to demand intensity rather than simply patient counts. Older patients more frequently present with overlapping cardiac, pulmonary, renal, vascular, and musculoskeletal conditions. That clinical complexity increases the value of systems capable of multiple focused assessments during one episode of care, particularly in home-care, outpatient, emergency, and critical-care workflows.
Key Restraints
Capital cost remains a practical constraint despite handheld price reductions. Traditional cart-based systems can cost substantially more than handheld devices, while total ownership cost also includes probe replacement, servicing, training, connectivity, and image-management infrastructure. A survey of ultrasound use in low- and middle-income countries identified equipment cost, access, and training as persistent barriers. This narrows the addressable market in public systems where imaging equipment competes with medicines, staffing, and basic infrastructure for limited budgets.
The constraint is most consequential where service networks are thin. A lower purchase price alone does not resolve downtime, repair logistics, consumables, or training continuity. Suppliers entering Latin America, rural Asia Pacific, and African markets must therefore match hardware pricing with local education and maintenance models if they are to convert unmet diagnostic need into sustained installed-base revenue.
Regulation also creates a meaningful entry barrier. Ultrasound devices regulated under FDA Class II requirements must generally meet 510(k) premarket requirements, and AI-enabled software adds validation, lifecycle-management, and post-market expectations. The European Medical Device Regulation imposes related obligations around clinical evaluation, monitoring, and device identification. A national multispecialty survey found that training, regulatory concerns around AI, electronic medical record compatibility, and confidence in algorithmic outputs remained barriers to wider POCUS adoption. [4]Shokoohi H et al. Multispecialty comparison of point-of-care-ultrasound use, training, and barriers: a national survey, 2024, link.springer.com
GMI Analyst View
The interaction of drivers and restraints divides the market into two commercial models. In mature health systems, demand is increasingly tied to enterprise workflow, reimbursement, and AI-supported clinical expansion, supporting premium software and replacement revenue. In lower-income settings, the binding constraint is not clinical need but the combined cost of acquisition, training, repair, and governance. That difference makes a single global pricing strategy structurally weak.
Regulatory capability offers incumbents a temporary advantage as AI functionality becomes central to product differentiation. However, it will not eliminate handheld price pressure. The most resilient suppliers will pair cleared clinical features with training, image management, and service infrastructure; companies competing only on hardware price may increase device access but face a narrower path to durable margins.
Point of Care Ultrasound Market Segment Analysis
By Type
Diagnostic devices generated approximately USD 2,637 million in 2025 and held 62.79% of market revenue. Their lead reflects the breadth of diagnostic POCUS use across cardiac assessment, obstetric evaluation, pulmonary examination, vascular access, trauma, and musculoskeletal imaging. AI-enabled automation is particularly important in this segment because it expands use beyond expert sonographers while preserving the requirement for clinician oversight.
Therapeutic devices accounted for USD 1,563 million, or 37.21%, of 2025 revenue. This category includes ultrasound-enabled treatment and procedural systems used in focused specialty settings. Its growth opportunities are tied to procedure-specific reimbursement, safety validation, and treatment monitoring rather than the broad diagnostic deployment model that supports diagnostic devices.
By Portability
Trolley-based devices held 63.41% of 2025 revenue, equivalent to approximately USD 2,663 million. Their continued lead reflects superior display size, multi-probe capability, workflow integration, and sustained performance during more complex or prolonged examinations. GE HealthCare introduced the Venue Sprint in September 2024, combining a tablet-format console with Vscan Air dual-probe connectivity and the Venue software platform. [5]GE HealthCare, GE HealthCare Introduces Elevated Venue Point of Care Ultrasound Solutions and New Tablet-Based Venue Sprint, September 19, 2024, investor.gehealthcare.com Philips launched its Flash Ultrasound System 5100 POC in June 2025 for anesthesia, critical care, emergency, and musculoskeletal care.
Handheld devices represented 36.59% of 2025 revenue. Their strategic importance exceeds their current revenue share because they reduce the cost of deployment per clinician or per outpatient location. Comparative research has found that leading handheld devices perform differently across clinical views rather than establishing one universal image-quality leader. As a result, software features, total ownership cost, workflow integration, and training support increasingly determine purchasing decisions.
By Application
Emergency medicine represented USD 752 million, or 17.78%, of 2025 revenue. Trauma assessment, cardiac tamponade evaluation, pulmonary examination, aortic screening, and procedural guidance make POCUS operationally valuable where delays affect treatment decisions. Cardiology accounted for USD 798 million, or 18.87%, supported by focused cardiac assessment and AI-guided ejection-fraction estimation. A systematic review of critical-care ultrasonography found that ultrasound-guided volume management was associated with lower mortality at the longest reported time point, although outcomes remain dependent on clinical protocol and operator competence.
Obstetrics & gynecology was the largest application at USD 938.4 million, or 22.19%, in 2025. POCUS supports pregnancy-location assessment, fetal viability, gestational estimation, placental evaluation, and gynecologic examination. The International Society of Ultrasound in Obstetrics and Gynecology issued POCUS practice guidelines in 2025, strengthening the framework for training and appropriate clinical use. [6]International Society of Ultrasound in Obstetrics and Gynecology, ISUOG Practice Guidelines: POCUS in Obstetrics and Gynecology, 2025, isuog.org Clarius received FDA clearance for its OB AI tool in June 2024, enabling automated fetal biometric estimation on handheld systems.
Urology generated approximately USD 476 million, or 11.27%, of 2025 revenue. Automated bladder-volume and prostate-measurement features are commercially relevant because they convert repetitive manual assessment into faster point-of-care workflow. Clarius received FDA clearance for Bladder AI in January 2024 and a later FDA-cleared Prostate AI capability. Vascular surgery accounted for approximately USD 458.7 million, or 10.84%, supported by vascular access, thrombosis assessment, and interventional workflow. Musculoskeletal applications represented 13.55%; portable ultrasound in ambulatory musculoskeletal consultations has been associated with fewer hospital referrals for injections and more procedures completed at the consultation site. Other applications accounted for 5.50%.
By End Use
Hospitals held the largest end-use share at 30.56% in 2025. Their procurement priorities increasingly include image archiving, credentialing, quality review, and integration with clinical information systems, not solely device performance. This favors vendors capable of supporting multi-department deployment.
Clinics accounted for USD 820.6 million, or 19.40%, of 2025 revenue. Handheld economics are particularly important in this setting because capital budgets rarely support high-end cart systems. Maternity centers represented USD 777.6 million, or 18.38%, reflecting sustained prenatal-monitoring demand and the formalization of obstetric POCUS practice.
ASCs generated approximately USD 1.0 billion and accounted for 24.04% of 2025 revenue. POCUS supports regional anesthesia, vascular assessment, and peri-procedural monitoring in outpatient procedure settings. Other end users, representing 7.62%, include field medicine, emergency medical services, diagnostic centers, and home-care settings. Vave Health launched its Universal Wireless Probe in March 2025 without subscription fees, targeting decentralized and individual-clinician use cases.
GMI Analyst View
Segment performance is shaped by a practical divide between high-complexity imaging and high-distribution imaging. Trolley-based systems retain an advantage where multi-probe versatility, workflow integration, and extended use justify higher capital spending. Handheld systems, in contrast, are shifting deployment from department-level assets toward clinician-, clinic-, and field-level tools. The resulting market does not suggest a simple substitution cycle; it points to different purchasing criteria by care setting.
Obstetrics & gynecology, cardiology, and emergency medicine provide the strongest established application base because each combines repeatable protocols with a clear consequence for timing of care. The next incremental revenue opportunity lies in converting handheld access into governed utilization through training, archiving, and specialty-specific AI. Suppliers that can deliver this operating layer will have an advantage in ASCs and clinics, where portability alone is insufficient to secure institutional adoption.
Point of Care Ultrasound Market Regional Analysis
North America
North America generated approximately USD 1.7 billion in 2025 and held 42.45% of the global market. The U.S. accounted for USD 1.4 billion in 2022, USD 1.5 billion in 2023, USD 1.6 billion in 2024, and USD 1.7 billion in 2025. CMS billing structures, high healthcare expenditure, and deployment in emergency departments, hospitals, and ASCs support the region's leading position. FDA-cleared AI capabilities are particularly relevant because U.S. health systems increasingly evaluate POCUS platforms on governance, image management, and enterprise compatibility as well as device specifications.
Canada adds demand through hospital networks, rural care, and remote community delivery, where portable imaging can reduce the need for transfers to centralized diagnostic facilities. Its adoption pathway depends heavily on provincial service design and access to trained operators.
Europe
Europe represented USD 1.1 billion, or approximately 25.95%, of 2025 revenue. Germany is the region's largest market, supported by healthcare spending, an aging population, and established demand for cardiovascular and musculoskeletal imaging. The UK's adoption case is tied to using portable imaging within hospital trusts and community care to improve access and reduce diagnostic delays. France, Spain, Italy, and the Netherlands contribute through hospital, outpatient, and specialty care procurement.
The EU Medical Device Regulation makes compliance capability commercially material. Larger vendors with established clinical-evaluation, documentation, and post-market systems can introduce regulated software features more readily than smaller entrants. This favors incumbent platforms in public-procurement environments, although budget discipline still limits premium-system replacement cycles in parts of Southern Europe.
Asia Pacific
Asia Pacific held approximately 22.17% of 2025 revenue and is projected to grow at approximately 8.4% CAGR. China is the region's most consequential volume opportunity and competitive manufacturing base, with Mindray and Chison positioned to leverage local distribution and lower-cost production. Mindray introduced the TE Air e5M in November 2025 as a whole-body wireless handheld system without subscription fees. [7]Mindray, Mindray Introduces TE Air e5M, November 19, 2025, mindray.com
Japan's aging demographic supports recurring demand in cardiac, vascular, and home-care use cases. India is characterized by expanding private-care capacity and a need for more decentralized diagnostics, but training and affordability remain decisive. Australia and South Korea offer more mature hospital infrastructure and stringent procurement standards. Across the region, the commercial contest is between premium enterprise platforms and lower-cost handheld adoption models.
Latin America
Latin America accounted for approximately 5.76% of 2025 revenue. Brazil and Mexico are the primary national markets, with Argentina representing a smaller growth opportunity. Demand is strongest in private hospitals, obstetric care, emergency medicine, and clinics, while public-sector expansion remains constrained by purchasing budgets and service capacity.
Handheld systems can improve affordability, but the regional growth case depends on service coverage and education as much as initial price. Vendors that can sustain local training and repair support are more likely to convert pilot deployments into institutional programs.
Middle East & Africa
The Middle East & Africa represented approximately 3.6% of 2025 revenue. Saudi Arabia's healthcare infrastructure investment and the UAE's concentration of tertiary-care facilities create demand for advanced POCUS platforms. South Africa remains a significant sub-Saharan market through private hospital demand in major urban areas.
Across lower-resource African settings, the value proposition is strongest in maternal health, emergency assessment, and decentralized care, but it requires structured training and maintenance. Cost and workforce constraints make broad deployment dependent on implementation programs rather than device availability alone.
GMI Analyst View
Regional growth will be heterogeneous in both revenue quality and competitive logic. North America is positioned to generate high-value demand through enterprise replacement, regulated AI upgrades, and ASC deployment, while Europe rewards suppliers with compliance infrastructure and credible public-procurement support. These markets are likely to remain the primary source of premium platform and software revenue.
Asia Pacific is the pivotal competitive region because it combines demand growth with the expansion of cost-competitive manufacturers. As handheld specifications converge, Chinese suppliers can exert pressure beyond their domestic market, particularly where buyers prioritize acquisition cost over integrated enterprise workflow. That pressure is less acute in regulated hospital systems where training, interoperability, and lifecycle support influence procurement.
Latin America and the Middle East & Africa contain considerable unmet diagnostic need, but their opportunity cannot be captured through low device pricing alone. Commercial success requires a delivery model that links affordable hardware with clinical education, repair capacity, and local support. The strategic moat is therefore moving from imaging hardware toward the ability to operationalize safe, repeatable POCUS use across distinct healthcare environments.
Point of Care Ultrasound Market Share & Competitive Landscape
Canon Medical Systems, Siemens Healthineers, Koninklijke Philips, Fujifilm, and GE HealthCare collectively held approximately 55% of global POCUS revenue. Their scale reflects broad imaging portfolios, established hospital relationships, regulatory infrastructure, and the ability to combine devices with service, training, and informatics. The remaining market is contested by specialized handheld suppliers and regional manufacturers, particularly as AI features and wireless connectivity reduce the historical advantage of large console systems.
Butterfly Network
Butterfly Network competes through its Ultrasound-on-Chip platform and enterprise workflow approach. Butterfly reported USD 82.1 million in 2024 revenue, compared with USD 65.9 million in 2023. [8]Butterfly Network, Annual Report / Form 10-K for fiscal year ended December 31, 2024, sec.gov Its strategic position depends on converting handheld deployment into recurring software, image-management, and institutional subscription revenue.
Canon Medical Systems
Canon Medical Systems serves POCUS applications through compact Viamo platforms. Its position is strongest where portable imaging is required without abandoning the display, workflow, and multi-application capabilities associated with established imaging vendors.
Clarius Mobile Health
Clarius Mobile Health is a pure-play wireless handheld supplier with a specialty-focused scanner portfolio and an expanding AI feature set. The company reported profitability and 20% growth in 2025, alongside nearly 7 million high-definition scans performed on its devices. Its model emphasizes specialty-specific software differentiation in a price-competitive handheld market.
Chison Medical Imaging
Chison Medical Imaging competes with the SonoEye handheld portfolio. Its price competitiveness and expanding international profile make it particularly relevant in Asia Pacific, Latin America, and Middle East & Africa markets, where premium-console economics are more difficult to sustain.
Esaote SpA
Esaote SpA maintains a European portable-ultrasound position through systems including MyLab platforms and the MyLab X1 Go. Its regional service presence and experience in musculoskeletal and specialty imaging support its relevance in European clinical settings.
Fujifilm
Fujifilm operates in POCUS through FUJIFILM Sonosite, one of the five leading revenue participants. FUJIFILM Sonosite launched the Sonosite MT in November 2025, combining a compact clamshell design with Synapse Synchronicity workflow integration. Its education-oriented model can strengthen retention where clinician training is a major adoption hurdle.
Fukuda Denshi
Fukuda Denshi participates through compact ultrasound systems, particularly in Japan and Asia Pacific. Its established cardiovascular-monitoring relationships provide a route to POCUS customers seeking aligned diagnostic and patient-monitoring workflows.
BenQ Medical Technology
BenQ Medical Technology supplies portable diagnostic imaging systems, primarily serving cost-sensitive Asia Pacific markets. Its electronics and display capabilities support positioning in settings seeking lower-cost imaging platforms.
GE HealthCare
GE HealthCare is a leading global participant through the Venue and Vscan Air families. Its strategy spans portable consoles, wireless handheld systems, AI-guided acquisition, and enterprise workflows. The Venue family updates announced in 2025 included Nerveblox AI and automated bladder-volume functionality.
Koninklijke Philips
Koninklijke Philips competes through Lumify, compact systems, and the Flash 5100 POC. The Flash 5100 POC combines encounter-based workflow and tele-ultrasound collaboration features, positioning Philips around integration across anesthesia, emergency, critical care, and musculoskeletal use cases.
Shenzhen Mindray
Shenzhen Mindray competes across trolley-based and wireless handheld systems, including the TE Air and TE X product lines. Its manufacturing economics and international distribution expansion position the company as a significant source of price pressure in the portable-ultrasound market.
Siemens Healthineers
Siemens Healthineers participates through the ACUSON Freestyle and ACUSON Juniper platforms. Its cable-free transducer design and interventional workflow capabilities are particularly relevant in vascular and procedure-driven settings.
SAMSUNG Healthcare
SAMSUNG Healthcare operates through Samsung Medison's portable systems, including the UGEO HM70A. Its portfolio addresses general imaging, obstetrics & gynecology, cardiology, and urology, with connectivity features supporting telehealth and remote review.
Viatom Technology
Viatom Technology participates in portable diagnostic and health-monitoring technologies that align with demand for miniaturized, wireless diagnostic tools. Its relevance is greatest in cost-sensitive handheld diagnostic settings.
Vave Health
Vave Health targets decentralized use with its Universal Wireless Probe. The company launched the single-transducer whole-body system in March 2025 and positioned it without subscription fees. This approach addresses individual clinicians and education-oriented buyers that may not adopt enterprise subscription models.
Recent Industry Developments
Need a specific section of this report?
Purchase regional analysis, country-level analysis, company profiles, or any other segment-level insights separately
based on your research needs.
Frequently Asked Question(FAQ) :
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Industry journals, trade publications, and specialized media.
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 20+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →